SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bliss GVS Pharma - Quaterly Results

01 Aug 2023 Evaluate
The sales for the June 2023 quarter moved down to Rs. 1089.92 millions as compared to Rs. 1472.80 millions during the year-ago period.Net profit of the cmpany stood at Rs. 74.96 millions for the quarter ended June 2023 a decline of -69.58% from Rs. 246.44 millions  in the same quarter last year.Operating profit for the quarter ended June 2023 decreased to 175.78 millions as compared to 377.81 millions of corresponding quarter ended June 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 1089.92 1472.80 -26.00 1089.92 1472.80 -26.00 5983.40 6363.57 -5.97
Other Income 65.27 186.34 -64.97 65.27 186.34 -64.97 507.66 326.28 55.59
PBIDT 175.78 377.81 -53.47 175.78 377.81 -53.47 1409.21 1418.26 -0.64
Interest 13.09 20.42 -35.90 13.09 20.42 -35.90 100.57 43.24 132.59
PBDT 162.69 357.39 -54.48 162.69 357.39 -54.48 1308.64 1402.47 -6.69
Depreciation 53.64 36.74 46.00 53.64 36.74 46.00 151.73 138.47 9.58
PBT 109.05 320.65 -65.99 109.05 320.65 -65.99 1156.91 1264.00 -8.47
TAX 34.09 74.21 -54.06 34.09 74.21 -54.06 302.14 337.36 -10.44
Deferred Tax 7.00 -12.25 -157.14 7.00 -12.25 -157.14 -42.10 7.68 -648.18
PAT 74.96 246.44 -69.58 74.96 246.44 -69.58 854.77 926.64 -7.76
Equity 104.22 103.81 0.39 104.22 103.81 0.39 104.15 103.68 0.45
PBIDTM(%) 16.13 25.65 -37.13 16.13 25.65 -37.13 23.55 22.29 5.68

Bliss GVS Pharma Share Price

258.35 -0.95 (-0.37%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×